FNY Investment Advisers LLC Reduces Holdings in Solventum Corporation $SOLV

FNY Investment Advisers LLC trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV) by 75.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440 shares of the company’s stock after selling 1,380 shares during the period. FNY Investment Advisers LLC’s holdings in Solventum were worth $33,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Independent Franchise Partners LLP increased its stake in shares of Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock worth $442,608,000 after purchasing an additional 4,217,570 shares in the last quarter. Davis Selected Advisers increased its stake in shares of Solventum by 0.8% during the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock worth $402,110,000 after purchasing an additional 41,524 shares in the last quarter. Boston Partners increased its stake in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after purchasing an additional 1,691,565 shares in the last quarter. Northern Trust Corp increased its stake in shares of Solventum by 3.3% during the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock worth $137,456,000 after purchasing an additional 58,373 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Solventum by 2.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock worth $89,268,000 after purchasing an additional 24,762 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SOLV shares. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. UBS Group initiated coverage on shares of Solventum in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 target price for the company. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Jefferies Financial Group initiated coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price for the company. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and an average target price of $84.89.

Solventum Stock Down 1.1%

Shares of SOLV opened at $71.49 on Friday. The firm has a market cap of $12.40 billion, a PE ratio of 33.10, a price-to-earnings-growth ratio of 2.94 and a beta of 0.50. The company’s fifty day moving average is $72.62 and its two-hundred day moving average is $72.13. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.